Intellia Therapeutics Q1 net loss narrows on lower R&D spending

INTELLIA THERAPEUTICS

11/05/2026 12:39

Overview

US gene editing firm's Q1 collaboration revenue fell yr/yr, net loss narrowed

Company presented positive Phase 3 lonvo-z data and began rolling BLA submission for HAE

Cash resources, including April offering, expected to fund operations at least into 2028

Outlook

Company expects to complete BLA submission for lonvo-z in second half of 2026

Intellia anticipates potential U.S. launch of lonvo-z in first half of 2027

Company expects existing cash resources to fund operations at least into 2028

Result Drivers

LOWER R&D SPENDING - Co said reduced research materials, contracted services, employee expenses, and stock-based compensation drove lower R&D costs

HIGHER G&A COSTS - Co attributed higher G&A expenses to commercial infrastructure buildout and increased legal expenses

Company press release: ID:nGNXbXBzp1

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q1 Collaboration Revenue
$15.05 mln
Q1 Net Income
-$96.23 mln
Q1 Basic EPS
-$0.81
Q1 Operating Expenses
$115.58 mln
Q1 Operating Income
-$100.53 mln


For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)